Uncategorized

  • Press Release
  • No Likes

ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program 150 150 Press Release

ABVC BioPharma Records With Total Milestone Payments Reaching $946,000, ABVC Deepens Its Ophthalmology Focus Through a High-potential Partnership With ForSeeCon SILICON VALLEY, CA – July 18, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical…

read more
  • Press Release
  • No Likes

ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology 150 150 Press Release

SILICON VALLEY, CA – June 26, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, proudly announces that a podcast with Biotech…

read more
  • Press Release
  • No Likes

ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment 150 150 Press Release

SILICON VALLEY, CA – June 24, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it has converted its…

read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value 150 150 Press Release

Silicon Valley, CA – (NewMediaWire) – June 03, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that its Board of…

read more
  • Press Release
  • No Likes

ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential 150 150 Press Release

FREMONT, CA – March 19, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment…

read more
  • Press Release
  • No Likes

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones 150 150 Press Release

ABVC BioPharma, Inc. Reports Q3 ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Received based on Executed Global Licensing Agreements that could provide…

read more
  • Press Release
  • No Likes

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales 150 150 Press Release
ABVC Biopharma, Inc. (NASDAQ: ABVC) today announced the signing of a legally binding term sheet with a prominent Chinese pharmaceutical company, Xinnovation Therapeutics Co., Ltd that, subject to definitive agreements, is for the exclusive licensing of ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China. read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.